[8-K] Theravance Biopharma, Inc. Reports Material Event

Rhea-AI Filing Summary

Theravance Biopharma notified investors that it has issued a press release and will hold a conference call presenting its financial results for the quarter ended June 30, 2025 and a business update.

The materials supporting the call are being furnished as Exhibit 99.1 (press release) and Exhibit 99.2 (slide deck). The filing states these exhibits are furnished and not filed, which limits certain statutory liabilities associated with filed disclosures.

Insights

Financial Analyst

TL;DR: Routine earnings disclosure notice; no financial metrics included here, so immediate investor impact is limited.

The 8-K informs investors that the company has released a press release and accompanying slides and will host a conference call on results for the quarter ended June 30, 2025. Because this filing does not include financial statements or numeric performance data, it provides notice of an upcoming disclosure rather than new substantive financial information. Investors must review the furnished exhibits or listen to the call to assess earnings, guidance, or changes to the business outlook.

Corporate Governance Expert

TL;DR: Disclosure appears procedurally standard; exhibits are clearly labelled as "furnished, not filed," which is customary to limit Section 18 liability.

The form follows common practice by furnishing the press release and slide deck as Exhibits 99.1 and 99.2 and stating that the materials are furnished rather than filed. This language signals standard legal treatment of the exhibits and does not expand the registrant's exposure to certain liability provisions. The filing indicates authorized distribution of these materials by senior management.

false 0001583107 0001583107 2025-08-12 2025-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC  20549

FORM 8-K

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): August 12, 2025

THERAVANCE BIOPHARMA, INC.

(Exact Name of Registrant as Specified in its Charter)

Cayman Islands		001-36033		98-1226628
(State or Other Jurisdiction of		(Commission File Number)		(I.R.S. Employer Identification
Incorporation)				Number)

C/O Theravance Biopharma US, LLC

901 Gateway Boulevard

South San Francisco, CA 94080

(650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Share $0.00001 Par Value		TBPH		NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company    ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition.

On August 12, 2025, Theravance Biopharma, Inc. (the “Company”) issued a press release and is holding a conference call regarding its financial results for the quarter ended June 30, 2025, and a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and a copy of materials that will accompany the call is furnished as Exhibit 99.2 to this Current Report.

The information in Item 2.02 and in Item 9.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act of 1934”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release dated August 12, 2025

99.2 Slide deck entitled Second Quarter 2025 Financial Results and Business Update

104 Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		THERAVANCE BIOPHARMA, INC.
Date:	August 12, 2025	By:	/s/ Aziz Sawaf
			Aziz Sawaf
			Senior Vice President and Chief Financial Officer

FAQ

What did Theravance Biopharma (TBPH) disclose in this Form 8-K?

The company disclosed that it has issued a press release and will hold a conference call presenting financial results for the quarter ended June 30, 2025 and a business update.

Which exhibits were furnished with the 8-K?

The filing states Exhibit 99.1 is the press release and Exhibit 99.2 is the slide deck entitled "Second Quarter 2025 Financial Results and Business Update."

Does the 8-K include financial metrics or results?

No. The Form 8-K notifies investors about the press release and call but does not include financial numbers or performance metrics; those are expected in the furnished exhibits.

What does "furnished, not filed" mean in this 8-K?

The filing explicitly states the exhibits are furnished and shall not be deemed filed, which limits certain statutory liabilities tied to filed disclosures under the Securities Exchange Act.

How can investors obtain the detailed results referenced in this filing?

Investors should review Exhibit 99.1 (press release) and Exhibit 99.2 (slide deck) or listen to the company's conference call to obtain the detailed financial results and commentary.